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Abstract
Antisense oligonucleotides are short nucleic acids designed to bind to specific messenger RNAs in order to
modulate splicing patterns or inhibit protein translation. As such, they represent promising therapeutic tools for
many disorders and have been actively developed for more than 20 years as a form of molecular medicine.
Although significant progress has been made in developing these agents as drugs, they are yet not recognized as
effective therapeutics and several hurdles remain to be overcome. Within the last few years, however, the prospect
of successful oligonucleotides-based therapies has moved a step closer, in particular for Duchenne muscular
dystrophy. Clinical trials have recently been conducted for this myopathy, where exon skipping is being used to
achieve therapeutic outcomes. In this review, the recent developments and clinical trials using antisense
oligonucleotides for Duchenne muscular dystrophy are discussed, with emphasis on the challenges ahead for this
type of therapy, especially with regards to delivery and regulatory issues.
Review
The development of the antisense oligonucleotides
(AO)-based approach started in the late 1970’s when the
oligonucleotides were used as tools to downregulate the
expression of specific genes [1]. The strategy was intui-
tive: oligonucleotides could be designed to hybridize
with a specific mRNA target and mediate its destruction
by RNaseH, an enzyme that destroys the RNA in a
DNA/RNA complex. Attention rapidly increased with
the development of antisense molecules for manipula-
tion of alternative splicing. In this context, oligonucleo-
tides can be used to modulate the ratio of splicing
variants or correct splicing defects, which opened far-
reaching implications in the treatment of a variety of
diseases. The requirements for oligonucleotides that
alter splicing are different from those for oligonucleo-
tides used to achieve downregulation. In particular, they
must not activate RNaseH, which would destroy the
pre-mRNA before it could be spliced. They must also
access their target pre-mRNAs within the nuclei of cells
to efficiently compete with splicing factors. Several types
of modified synthetic oligonucleotides fit these criteria.
Among these, oligonucleotides with modifications to
the 2’ position, such as 2’-O-methyl (2’OMe), 2’-O-
methoxyethyl (2’O-MOE) and 2’-O-aminopropyl, are
RNaseH inactive and display higher nuclease resistance
and affinity for target sequences than their 2’-deoxy
counterparts. Similar characteristics are found in oligo-
nucleotides with backbones based on morpholino, pep-
tide nucleic acid (PNA), locked nucleic acid (LNA),
phosphoramidate and methyl-phophonate derivatives.
These advances in the development of antisense chemis-
tries have led to numerous studies investigating the
therapeutic potential of antisense technology (for review
see [2]). However, despite early promise, the therapeutic
application of AO has proved to be difficult and has
been very slow entering the market and standard of
care. Only a single AO compound has been approved by
the Food and Drug Administration (FDA) so far. Indeed,
no other AO has won marketing approval since Vitra-
vene (Fomivirsen), developed by ISIS Therapeuticals was
approved in 1998 for use against cytomegalovirus-
induced retinitis by intravitreus injection [3]. Among the
hurdles that have slowed the progress of AO drugs into
the clinical area are off-target toxic effects and low effi-
cacy partly due to delivery difficulty.
Recent developments are achieving success overcom-
ing some of these obstacles. In particular, the use of AO
in clinical trials for Duchenne muscular dystrophy
(DMD) has recently demonstrated very encouraging
results. The remainder of this review focuses on this
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application. We will first review the principle of this
approach and the clinical data from these initial trials
and we will then discuss the promises and challenges of
AO based therapy for DMD, focusing on systemic deliv-
ery and regulatory issue.
DMD background and rationale of exon skipping therapy
Duchenne muscular dystrophy (DMD) is a lethal
X-linked progressive muscle-wasting disease caused by
mutations, typically large deletions in the DMD
gene, the largest gene in the human genome [4]. Most
mutations, including deletions (approximately 65%),
duplications, point mutations or other small gene rear-
rangements disrupt the open reading frame, leading to
aberrant translation and, therefore, to the absence of the
essential muscle protein dystrophin. Dystrophin is loca-
lized at the sarcolemma of the muscle fiber and forms a
dystrophin glycoprotein complex (DGC) with dystrogly-
can, sarcoglycan, and syntrophin/dystrobrevin com-
plexes. The DGC provides a mechanical and signalling
link between the actin cytoskeleton and the extracellular
matrix [5]. The absence of dystrophin leads to recurrent
muscle fiber damage during contraction and muscle
fibers are eventually replaced by adipose and fibrotic tis-
sue. Patients with DMD suffer from progressive loss of
muscle function which generally leads to wheelchair
dependency by the age of 13 and premature death,
mostly before the age of 30 [6].
Interestingly, the allelic disease Becker muscular dys-
trophy (BMD), which results in a much milder pheno-
type, is mainly caused by mutations maintaining the
open reading frame and allowing the production of a
partially deleted but functional dystrophin [7]. Anti-
sense-mediated exon-skipping strategies for DMD aim
to remove the mutated exon alone or together with
additional exons to restore the reading frame and
consequently induce the expression of “BMD-like” shor-
tened forms of dystrophin retaining crucial functions
(Figure 1). Although the exon-skipping approach
appears to be applicable to a large proportion of patients
(possibly up to approximately 83% of all DMD patients
[8], one should keep in mind that this will not offer a
definite cure but an improvement towards a BMD-like
phenotype depending on the functionality of the
restored dystrophin.
The principle of the exon-skipping therapy for DMD
has first been demonstrated by Pramono et al. in 1996
in lymphoblastoid cells and by Dunckley et al. in 1998
in cultured mouse cells in vitro [9,10]. Since then,
numerous in vivo studies have provided pre-clinical evi-
dence for the therapeutic potential of an antisense strat-
egy for DMD in several animal models. In particular,
the mdx mouse model, which harbors a nonsense muta-
tion in exon 23, has been used extensively to test
efficacy of the AO approach using various oligonucleo-
tides chemistries such as 2’OMe [11], phosphorodiami-
date morpholino oligomers (PMO) [12,13], LNA or
PNA [14,15] (Figure 2). Intramuscular and systemic
injections in canine models of the disease have also
demonstrated restoration of dystrophin expression asso-
ciated with functional benefits [16].
Following the very encouraging results obtained on
these animal models, groups both in the Netherlands and
in the UK have worked towards clinical evaluation of the
antisense mediated exon-skipping in DMD patients.
Phase I clinical trials provide proof of principle of
oligonucleotide-based therapy for DMD
The clinical application of antisense-mediated exon-
skipping for DMD raises several considerations. Among
these, the genetic heterogeneity of DMD patients means
that this approach is mutation-specific and as such an
example of personalized medicine. According to the Lei-
den muscular dystrophy database, exon-skipping is
potentially applicable to approximately 83% of all DMD
patients if single and double exon-skipping of deletions,
small mutations and duplications can be achieved [8].
Fortunately, the majority of deletions clusters into hot-
spot regions between exons 43 and 53, suggesting that
skipping of the same group of exons is applicable to
large groups of patients. The most notable example is
exon 51 skipping, which is applicable to 13% of all
patients and has for that reason been targeted for both
phase I clinical trials.
The Dutch group together with the RNA therapy
company Prosensa selected a 20-mer antisense oligonu-
cleotide of 2’OMe phosphorothiate RNA chemistry tar-
geting exon 51 (PRO051). Four DMD patients were
injected locally in the tibialis anterior muscle with a sin-
gle dose of 0.8 mg PRO051. Four weeks after the injec-
tion, a small biopsy was analyzed for each patient and
revealed a restoration of dystrophin in the vast majority
of muscle fibers at levels varying between 17 and 35%,
in the absence of treatment related adverse effect [17].
The UK team in collaboration with AVI Biopharma
selected a PMO antisense oligonucleotide, based on pre-
clinical studies with this backbone chemistry [12,13,18].
The 30-mer PMO optimized to skip exon 51 (AVI-
4658) [19] was injected unilaterally into the extensor
digitorum brevis muscles of seven patients, in a single-
blind, dose-escalation protocol that included a placebo
control administered to the contralateral extensor digi-
torum brevis muscle. Results from this trial demon-
strated that PMO oligonucleotides were well tolerated
by all patients and that dystrophin protein were
expressed at up to 42% of normal levels in dystrophin
positive fibers of patients treated with the higher dose of
0.9 mg [20].
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Although there are similarities and differences
between the two studies (summarized in Figure 3), they
both report unequivocal expression of dystrophin at
similar concentrations without any drug-related adverse
effect with either chemistry. These very encouraging
results confirmed the proof of the principle of the anti-
sense oligonucleotide based therapy for DMD. However,
they represent only a first step as intramuscular injec-
tion of each individual muscle is not feasible. The next
step which both groups are currently undertaking is to
deliver the antisense oligonucleotide systemically.
Systemic delivery of Antisense oligonucleotides for DMD
The systemic delivery of AO for the treatment of DMD
has been demonstrated in mouse and dog models with-
out safety issues. Intramuscular clinical trials performed
with either a 2’OMe (PRO051) or a PMO (AVI-4658)
provided a proof-of-principle efficacy study in man.
Figure 1 Antisense-mediated exon skipping rationale for DMD. Patients with Duchenne muscular dystrophy have mutations which disrupt
the open-reading frame of the dystrophin pre-mRNA. In this example, exon 50 is deleted, creating an out-of-frame mRNA and leading to the
synthesis of a truncated non-functional or unstable dystrophin (left panel). An antisense oligonucleotide directed against exon 51 can induce
effective skipping of exon 51 and restore the open reading frame, therefore generating an internally deleted but partly functional dystrophin
(right panel).
Figure 2 Chemistries used for the exon skipping approach.
Artificially developed AO such as peptide nucleic acid (PNA), 2’O-
Methyl-phosphorothiate-antisense oligonucleotides (2’OMeAO),
phosphorodiamidate morpholino oligomer (PMO) and peptide
conjugated PMO (PPMO) are shown for comparison with DNA and
RNA. PNA’s backbone is composed of repeating N-(2-aminoethyl)-
glycine units linked by peptide bonds, PMO have a morpholine ring
instead of the deoxyribose ring in DNA or ribose ring in RNA and
2’OMeAO are similar to RNA but methylated at the 2’-OH position
of the ribose ring.
Figure 3 Comparison of the two clinical trials reporting
intramuscular injection of AO in patients with DMD [17,20].
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Both studies have been followed by repeated systemic
administration studies. The Dutch consortium recently
completed a phase I/IIa trial involving four groups of
DMD boys receiving escalating doses of 0.5, 2.0, 4.0 and
6.0 mg/kg of 2’OMe weekly for five weeks. While the
results of this study has not yet been published, Dr Goe-
mans reported at the World Muscle Society (WMS)
meeting in 2009 that PRO051 was well tolerated in each
DMD patient and that novel dystrophin expression was
observed [21]. All boys who participated in this study
entered an open label extension study, receiving weekly
subcutaneous injections of 6 mg/kg regardless of earlier
dose. Twenty-four-week follow-up data presented at the
WMS meeting in 2010 reported that this treatment was
generally well tolerated over the 24-week period and
that encouraging gains in the six-minute walk test were
observed in some boys [22]. Encouraging results have
also been announced by the UK consortium and AVI
Biopharma who have completed their systemic study
enrolling 19 patients receiving weekly IV administrations
of AVI-4658 (six cohorts receiving 0.5, 1.0, 2.0, 4.0, 10.0
or 20.0 mg/kg). Dr Shrewsbury reported at the WMS
meeting in 2010 that the study drug was well tolerated
and that exon 51 skipping was detected in patients at
the 2 mg/kg dose and above, giving rise to expression of
dystrophin [23]. These preliminary results sound pro-
mising and raise expectations to a high level for the sys-
temic treatment of DMD. However, one should not
forget that many challenges remain, especially regarding
the delivery to all affected tissues in DMD.
Current challenges regarding delivery
Although results from initial trials appear very encoura-
ging, there are several issues that pose challenges for the
use of AO, either 2’OMe or PMO- as effective and
affordable drugs for DMD. The first obstacle with both
chemistries remains the poor cellular uptake and relative
rapid clearance from the circulation, which require
repeated administration to achieve some therapeutic
efficacy. Experiments in animal models demonstrated
that large doses ranging from 100 mg/kg/wk in mouse
[24,25] to 200 mg/kg/wk in dogs [16] over several weeks
were required for functional improvement. The fact that
both animal models required large doses, despite their
difference in body surface area, suggests that similar
dose range might be required to achieve efficacy in
humans. If so, the cost of an AO drug, type PMO for
example, for life-long treatment will probably be prohi-
bitive for many patients.
A second major hurdle with the systemic administra-
tion of AO is the high variability in exon-skipping effi-
ciency among muscle types. Again data collected from
mice and dog studies have shown that some muscles
respond better than others. Repeated intravenous
injections of 100 mg/kg of PMOE23 to mdx mice
resulted in higher restoration of dystrophin in quadri-
ceps, abdominals, intercostals and gastrocnemii muscles
compared to diaphragm, biceps, triceps and tibialis ante-
rior, for example [24]. Even within the most responsive
muscles, dystrophin was not uniformly expressed with
detection of patches of dystrophin-positive fibers and
patches of dystrophin-negative fibers. This may be
because the uptake of AO is restricted to leaky muscle
fibers, indicating that AO’s efficacy in humans will
depend on the number of leaky muscle fibers.
An additional problem compromising the therapeutic
potential of AO-mediated exon-skipping for DMD at
the moment is that both AO chemistries have shown
very little efficacy in the cardiac muscle [24,26]. A more
recent study showed that even higher doses (nine doses
of 100 mg/kg) induced only very low level (1 to 2%) of
dystrophin expression in the heart with both 2’OMe and
PMO [25]. Only when used in huge amounts such as
300 mg/kg and 3,000 mg/kg, could PMOE23 restore
about 5% and 30% respectively of wild-type dystrophin
level in the heart of mdx mice [27]. Such extreme doses
would be unsustainable for repeated administration and
the long-term treatment required for DMD. Clinically,
cardiomyopathy is the second leading cause of death in
patients with DMD in countries where ventilator ther-
apy has been introduced, accounting for 10 to 40% of
deaths in DMD populations [4], which implies a clear
need for a cardiac dystrophin correction. The reasons
for the low efficiency of cardiac dystrophin restoration
are unclear, but are probably related to the poor ability
of unmodified oligonucleotides to penetrate the heart.
Recent developments using cell penetrating peptides
(CPP)-conjugated PMO (PPMO) have addressed most
of these delivery issues and could, therefore, represent
an effective strategy to reduce dose level and dose fre-
quency, as well as delivering the AO to non-leaky fibers
and the heart [27-31].
Challenges and promises of PPMO for DMD
Since the first study reported the enhanced PMO uptake
mediated by a cell penetrating peptide, resulting in
widespread restoration of dystrophin in mdx mice in
2007 [13], PPMO have gained attention for the systemic
treatment of DMD. Many laboratories have demon-
strated uniform and high levels of dystrophin expression
through the whole body using much lower dose of
PPMO (ranging from 6 to 25 mg/kg) compared to PMO
(around 100 mg/kg) [28,32,33]. PPMO are much more
effective than PMO because of the ability of CPP to
facilitate the internalization of PMO through an active
process, unlike the passive diffusion process for PMO.
PPMO are internalized by nearly all muscle cells, and,
therefore, not restricted to leaky fibers as are PMOs
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[31]. Moreover, evidence of significantly restored cardiac
dystrophin has been demonstrated in PPMO-treated
mice [27-30]. A single intravenous injection of 30 mg/kg
of PPMO indeed restored dystrophin to almost normal
levels in the cardiac and skeletal muscles of mdx mice,
which leads to an increase in muscle strength and, more
importantly, improvement of cardiac function [30].
Taken all together, these studies indicate that PPMO
can be used at a much lower dose than PMO and can
achieve more widespread restoration of dystrophin
throughout the whole body’s muscle including the heart.
These characteristics would qualify PPMO as an ideal
candidate for the systemic treatment of DMD compared
to unconjugated AO. However, the toxicity of current
PPMO chemistry poses a challenge for determination of
an effective and safe regimen in man. One PPMO tar-
geting human exon 50 (AVI-5038) is currently in pre-
clinical development for DMD and has been tested in
the cynomolgus monkey [31]. This PPMO was found to
cause mild tubular degeneration in the kidneys of mon-
keys injected weekly with 9 mg/kg for four weeks,
although the same peptide conjugated to PMOE23 did
not exhibit any toxic effect in the kidneys of mdx mice
treated with higher doses (30 mg/kg biweekly for three
months) [30]. This indicates that monkeys are more
sensitive to PPMO-related toxicity than mice. The nat-
ure of the toxicity is not well understood, but it is likely
to be due to the cationic nature of the peptide. A dose
threshold for the toxicity seems to exist, which level
depends on the amino acid composition of the peptide
[31]. Another major concern that arises with the use of
peptides as delivery enhancers is the immune response
they might elicit. It is, therefore, extremely important to
monitor such a response in animal models like Wu
et al. did [30]. The use of unnatural amino acids in
some of these peptide sequences most likely contributes
to the lack of immunogenicity. However, the principle
of precaution together with the fact that immunogeni-
city varies considerably between species would argue for
longer term studies in other species than mice. These
pre-clinical data provide valuable information and
emphasize the difficulty in predicting exon-skipping effi-
cacy/toxicity across species and to plan efficient yet safe
escalation in human patients.
Current regulatory challenges of personalized medicine
Despite the very promising results of the initial trials tar-
geting exon 51, the clinical applicability of the AO-
mediated exon-skipping approach for DMD still faces a
major hurdle regarding regulatory approval. The
sequence specific nature of the strategy has implications
for future personalised medicine. Although skipping of
exon 51 is applicable to a large group of DMD patients
(13%), it will not benefit the other 87% and, therefore,
other AO need to be developed to target other dystro-
phin exons [8]. From the Leiden muscular dystrophy
database, it has been estimated that skipping 10 exons
might be beneficial in up to 40% of all patients and that
this could be increased to 83% if single and double skip-
ping of point mutations, duplications and small muta-
tions could be achieved [8]. One can easily envision that
numerous specific sequences will be required to effec-
tively treat such a large proportion of patients. If each
AO is considered a new drug, which is the current FDA
regulation, then each of them will have to go through the
expensive and lengthy clinical trial stages. On top of
being an insuperable barrier in terms of money and time,
it might be very problematic to find enough patients to
even perform clinical trials. Some AO may be applicable
to a very restricted number of patients, such as those tar-
geting exons 71, 72, 75, 77 or 78 (representing 0.02% of
all mutations) [8]. A practical resolution of this problem
would be to consider AOs (PMO or 2’OMe) as one drug,
even if their sequences are different. Therefore, the reali-
zation of the clinical applicability of AO-based exon-
skipping as a treatment for DMD might lie in the
approval of antisense sequences as a class of drugs. This
type of approval would be a first for the FDA, but the
prospect of personalized molecular medicine might jus-
tify such a change in approach.
Conclusions
Within the last few years, oligonucleotides-based thera-
peutics have moved a step closer to clinical applicability,
especially for DMD. The first clinical trials in DMD
patients have demonstrated the proof of the principle of
exon-skipping in man and shown very encouraging
results. Although this type of therapy faces some chal-
lenges, in particular regarding delivery to all affected tis-
sues, recent pre-clinical work using cell-penetrating
peptide suggests that solutions are close at hand. Pro-
gress made in the context of DMD may also impact the
development of experimental therapies for many other
disorders, such as spinal muscular atrophy (SMA) or
myotonic dystrophy for which AO-mediated approaches
have been investigated.
Finally, the success of oligonucleotides-based therapies
will require close cooperation with regulatory agencies
both in Europe and in the USA, which need to look at
such “personalized medicine” in a new way to allow safe
and cost-effective testing for rapid clinical development.
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